Literature DB >> 24548803

FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model.

Cindy Kunne1, Alexandra Acco2, Suzanne Duijst1, Dirk R de Waart1, Coen C Paulusma1, Ingrid Gaemers1, Ronald P J Oude Elferink3.   

Abstract

It has been established that bile salts play a role in the regulation of hepatic lipid metabolism. Accordingly, overt signs of steatosis have been observed in mice with reduced bile salt synthesis. The aim of this study was to identify the mechanism of hepatic steatosis in mice with bile salt deficiency due to a liver specific disruption of cytochrome P450 reductase. In this study mice lacking hepatic cytochrome P450 reductase (Hrn) or wild type (WT) mice were fed a diet supplemented with or without either 0.1% cholic acid (CA) or 0.025% obeticholic acid, a specific FXR-agonist. Feeding a CA-supplemented diet resulted in a significant decrease of plasma ALT in Hrn mice. Histologically, hepatic steatosis ameliorated after CA feeding and this was confirmed by reduced hepatic triglyceride content (115.5±7.3mg/g liver and 47.9±4.6mg/g liver in control- and CA-fed Hrn mice, respectively). The target genes of FXR-signaling were restored to normal levels in Hrn mice when fed cholic acid. VLDL secretion in both control and CA-fed Hrn mice was reduced by 25% compared to that in WT mice. In order to gain insight in the mechanism behind these bile salt effects, the FXR agonist also was administered for 3weeks. This resulted in a similar decrease in liver triglycerides, indicating that the effect seen in bile salt fed Hrn animals is FXR dependent. In conclusion, steatosis in Hrn mice is ameliorated when mice are fed bile salts. This effect is FXR dependent. Triglyceride accumulation in Hrn liver may partly involve impaired VLDL secretion.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile acid; CYP450-reductase; FXR; Fatty liver; Hrn

Mesh:

Substances:

Year:  2014        PMID: 24548803     DOI: 10.1016/j.bbadis.2014.02.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment.

Authors:  Hozeifa Mohamed Hassan; Hongli Guo; Bashir Alsiddig Yousef; Mounia Guerram; Aida Mejda Hamdi; Luyong Zhang; Zhenzhou Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 2.  Nuclear receptors and nonalcoholic fatty liver disease.

Authors:  Matthew C Cave; Heather B Clair; Josiah E Hardesty; K Cameron Falkner; Wenke Feng; Barbara J Clark; Jennifer Sidey; Hongxue Shi; Bashar A Aqel; Craig J McClain; Russell A Prough
Journal:  Biochim Biophys Acta       Date:  2016-03-04

3.  Dexamethasone Pretreatment Alleviates Isoniazid/Lipopolysaccharide Hepatotoxicity: Inhibition of Inflammatory and Oxidative Stress.

Authors:  Hozeifa M Hassan; Hongli Guo; Bashir A Yousef; Ding Ping-Ping; Luyong Zhang; Zhenzhou Jiang
Journal:  Front Pharmacol       Date:  2017-03-15       Impact factor: 5.810

4.  Improved oxygenation dramatically alters metabolism and gene expression in cultured primary mouse hepatocytes.

Authors:  Eduardo H Gilglioni; Jung-Chin Chang; Suzanne Duijst; Simei Go; Aziza A A Adam; Ruurdtje Hoekstra; Arthur J Verhoeven; Emy L Ishii-Iwamoto; Ronald P J Oude Elferink
Journal:  Hepatol Commun       Date:  2018-02-09

5.  Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Authors:  Ahad Eshraghian
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

Review 6.  Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Tetyana Falalyeyeva; Luigi Boccuto; Olena Tsyryuk; Nazarii Kobyliak
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

7.  Pathogenesis of NASH: The Impact of Multiple Pathways.

Authors:  Mazen Noureddin; Arun J Sanyal
Journal:  Curr Hepatol Rep       Date:  2018-10-31

Review 8.  Molecular Pathogenesis of NASH.

Authors:  Alessandra Caligiuri; Alessandra Gentilini; Fabio Marra
Journal:  Int J Mol Sci       Date:  2016-09-20       Impact factor: 5.923

9.  Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.

Authors:  Prue M Pereira-Fantini; Susan Lapthorne; Cormac G M Gahan; Susan A Joyce; Jenny Charles; Peter J Fuller; Julie E Bines
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-03-06

10.  Farnesoid X receptor and bile acids regulate vitamin A storage.

Authors:  Ali Saeed; Jing Yang; Janette Heegsma; Albert K Groen; Saskia W C van Mil; Coen C Paulusma; Lu Zhou; Bangmao Wang; Klaas Nico Faber
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.